NDRI: National Disease Research Interchange - Publications

You are currently filtering by: ovary

Cancer • 2015 • Clinical Cancer Research 21(18): 4165-4173. PMID: 26015513.

Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions.

Damelin M, Bankovich A, Park A, et al

Full Article

NDRI is a Not-For-Profit (501c3) Corporation.

CAP Accredited